Video Analysis for Neovista
February 16, 2006
320 x 240
5 / 5 (28 ratings)
5 / 5
EST. TOTAL REVENUE
$0 - $0
EST. MONTHLY REVENUE
$0 - $0
EST. YEARLY REVENUE
AVG. DAILY VIEWS
AVG. DAILY LIKES
* We try our best to gather the video's growth rate. This is an estimate for a cumulative growth of views.
There is no description for this video.Read more »
NeoVista | OneMedPlace | Age-Related Macular …
NeoVista develops and markets technology designed to treat wet age-related macular degeneration using targeted strontium-90 beta radiation.
Welcome to Neo Vista
Who Are We. Neovista equipment's. neovista is the leading distributor of food machines for the confectionery and food industry . Our machines are built to the …
NeoVista, Inc. - Financial Report | Annual Revenue | Stock
NeoVista, Inc. is a privately-held, venture capital backed medical device company. NeoVista is enaged in the development of medical technologies that advances the ...
John N. Hendrick - Executive Bio, Compensation History ...
View John N. Hendrick, Former President, Chief Executive Officer and Board Member at NEOVISTA INC, Newark, CA, executive profile on Equilar Atlas to see current ...
Neovista Newsfeed | News and information from Neovista ...
News and information from Neovista Consulting ... Potholes? There’s an App for That September 20, 2012 Posted by Jeff Fuchs in government, lean.
NeoVista, Inc. Announces Initial VIDION(R) Shipments
November 9, 2009. BV4 Portfolio Company NeoVista, Inc. Announces Initial VIDION(R) Shipments Hospital in Pisa, Italy is First in World to Receive Revolutionary ...
NeoVista Unveils 18-Month Data on Novel Wet AMD …
SCOTTSDALE, Ariz., Sept. 29 /PRNewswire/ -- NeoVista, Inc. made public yesterday 18-month data from the company's Phase II feasibility study examining its novel ...
NeoVista®, Inc. Receives CE Mark Approval for VIDION® …
NeoVista, Inc. NeoVista's novel device takes first step towards commercialization in European market. Fremont, CA, August 4, 2009 -- NeoVista, Inc. today announced ...
A Study of the NeoVista Ophthalmic System for the ...
A Study of the NeoVista Ophthalmic System for the Treatment of Subfoveal CNV Associated With Wet AMD in Patients That Require Persistent Anti-VEGF Therapy …
Neovista - Design - Global Concept - Architecture ...
neovista design. neovista; management; hotels; offices; embassy; commercial; housing & condo; residence; bar & restaurant; consulting; art & graphic; furniture ...
MasPar reborn as NeoVista
MasPar Computer Corp., which specializes in building high-performance parallel-processing solutions in the federal market, is reinventing itself this week as NeoVista Solutions Inc. and bringing to market a suite of high-end data-mining tools for open ...
Company Overview of NeoVista, Inc.
NeoVista, Inc. develops medical technologies for use in the treatment of wet age-related macular degeneration that causes blindness in men and women over the age of 50 years. It develops VIDION ANV Therapy system that is offered as an adjunct therapy …
NeoVista Unveils 18-Month Data on Novel Wet AMD Therapy at Retina Society Meeting
SCOTTSDALE, Ariz., Sept. 29 /PRNewswire/ -- NeoVista, Inc. made public yesterday 18-month data from the company's Phase II feasibility study examining its novel epiretinal brachytherapy for treatment of the wet form of age-related macular degeneration …
NeoVista, a radiation treatment device maker, to raise $26M
Got email marketing? We've got best practices from LivingSocial and estate sale guru Everything But The House in our next Insight webinar. Radiation treatment device maker NeoVista wants to raise up to $26 million in a Series B financing in time to begin ...
FDA approves expansion of NeoVista's phase 3 study for wet AMD
NeoVista, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted the company's request to expand the number of sites participating in its pivotal Phase 3 trial from 10 to 30 in the United States. The approved expansion of ...
COMPANY NEWS; ACCRUE TO ACQUIRE NEOVISTA FOR $140 MILLION
Accrue Software Inc., a maker of Internet analysis software, agreed yesterday to buy the closely held NeoVista Software Inc. for about $140.3 million in stock to move into electronic direct marketing. Accrue will pay 2.4 million shares of its common stock.
FDA Approves Compassionate Use of Investigational Treatment for AMD
The FDA has given compassionate approval to use NeoVista‘s Epiretinal Brachytherapy (a procedure that is presently in Phase III studies) to treat a woman’s wet-AMD (age-related macular degeneration). The company hopes that its NeoVista Epi-Rad 90 ...
New Hope In Treatment Of Wet AMD
NeoVista, Inc. made public today at the American Academy of Ophthalmology meeting the company’s one-year results from their MERITAGE Study. This study was designed to examine NeoVista’s novel Epimacular Brachytherapy procedure when used …
Oxford Finance Corporation And GE Capital Provide $20 Million Senior Credit Facility To NeoVista®, Inc.
March 17, 2011 /PRNewswire/ -- Oxford Finance Corporation (Oxford), a subsidiary of Sumitomo Corporation, today announced that it and GE Capital, Healthcare Financial Services closed a $20 million round of debt financing for NeoVista®, Inc. These funds ...
NeoVista, Inc. Deals & Alliances: New analysis published
NeoVista, Inc. (NeoVista) is a medical device company. The company develops intraocular epiretinal radiation device. It offers medical technologies for the treatment of wet age-related macular degeneration that causes blindness in men and women over the ...
- Show More